Comparative Pharmacology
Head-to-head clinical analysis: DETROL versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL versus HICON.
DETROL vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Anticholinergic
Anticholinergic